RRX-001 is under clinical development by EpicentRx and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RRX-001’s likelihood of approval (LoA) and phase transition for Metastatic Colorectal Cancer took place on 16 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RRX-001 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RRX-001 is under development for the treatment of advanced solid tumors, metastatic colorectal cancer, brain metastases, small-cell lung cancer, Parkinson's disease, relapsed and refractory multiple myeloma, non-small cell lung cancer, radiation induced oral mucositis, small cell lung cancer, epithelial ovarian cancer, high grade neuroendocrine tumors, lymphoma, cerebral malaria, newly diagnosed high-grade glioma, including anaplastic glioma, glioblastoma, metastatic castration resistant neuroendocrine prostate cancer (NEPC), gliosarcoma, liver cancer, acute radiation syndrome, inflammation and recurrent or progressive malignant solid and central nervous system tumors. It is administered through intravenous, subcutaneous route and as a hepatic artery infusion. It is a prototypic dinitroazetidine molecule. The drug candidate has dual mode of action by acting as antivascular and anti-tumor agent. It acts by targetting CD47-SIRP alpha.
It was also under development for advanced cholangiocarcinoma, elapsed Multiple myeloma,cerebral (fatal) malaria, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, refractory multiple myeloma and lymphoma . The drug candidate is being developed based on CyNRGY platform.
EpicentRx, formerly RadioRx, is a biopharmaceutical company that discovers and develops therapies for cancer and chronic diseases. The company utilizes CyNRGY platform to develop RRx-001, a NLRP3 inhibitor to treat small cell lung cancer, neurodegenerative diseases, liver and blood cancer; and eLoop administration device to optimize delivery of Intravenous administered treatments. It is also investigating AdAPT-001, an oncolytic virus that carries transformative growth factor beta trap transgene to neutralize TGF-ß within the infected tumor. EpicentRx works in collaboration with Texas Children’s Cancer Center to examine safety and benefits of RRx-001 in patients with malignant solid and central nervous tumors. EpicentRx is headquartered in San Diego, California, the US.
Quick View RRX-001 LOA Data
|Highest Development Stage|